Characterization, antibacterial and antibiofilm evaluation of biosynthesized silver nanoparticles from Pseudomonas aeruginosa against drug resistant Acinetobacter baumannii


  • Talar Ibrahim Hasan Department of Biology, College of Science, Salahaddin University- Erbil, Iraq
  • Akhter Ahmed Ahmed Department of Biology, College of Science, Salahaddin University- Erbil, Iraq



drug resistance, biofilm, Acinetobacter baumannii, biogenic silver nanoparticles


Antimicrobial resistance is regarded as one of the top three terrible events threatening the worldwide existence of humans Here of, Acinetobacter baumannii evolved as the most challenging pathogen threatening to initiate the post-antibiotic era.

Their ability to withstand antibiotics is attributed to a set of virulence determinants in particular biofilms which are known to enhance pathogenesis and drug resistance potency. Studies regarding green silver nanoparticles (AgNP)s as an alternative treatment modality to antibiotics increased over recent years. Considering these facts, we aimed to explore the antibiofilm effect of AgNPs in the multi-drug-resistant Acinetobacter baumannii. AgNPs were bio-fabricated by Pseudomonas aeruginosa and characterized via FTIR, UV-Vis, XRD, EDS, and SEM. Well-diffusion was used to screen the antimicrobial effects of AgNPs. Minimal-inhibitory concentrations of AgNPs were determined to study their antibiofilm effect at sub-inhibitory concentrations (SIC). Results showed that all isolates were biofilm producers and portrayed high resistance to the tested antibiotics. Characterization results supported the successful fabrication of crystalline nanoparticles. Exposure of the isolates to the bacteriogenic AgNPs resulted in pronounced inhibition zones and reduced biofilms at SICs values. These results indicate that Pseudomonas aeruginosa can be employed to produce AgNPs with an aptitude to disrupt biofilm development and growth in the multi-drug resistant Acinetobacter ­­­­­baumannii.


- Boucher HW. Bad Bugs, No Drugs 2002-2020: progress, challenges, and call to action. Transactions of the American Clinical and Climatological Association, 2020;131:65. 2020;131:65-71.

- Ventola CL. The antibiotic resistance crisis: part 1: causes and threats. Pharmacy and Therapeutics. 2015;40(4):277-83.

- Laws M, shaaban A, Rahman KM. Antibiotic resistance breakers: current approaches and future directions. FEMS Microbiology Reviews, 2019;43(5):490-516.

- Uddin TM, Chakraborty AJ, Khusro A, Zidan Bmrm, Mitra S, Emran TB, et al. Antibiotic resistance in microbes: history, mechanisms, therapeutic strategies and future prospects. Journal of Infection and Public Health. 2021;14(12):1750-66.

- Aslam B, Khurshid M, Arshad MI, Muzammil S, Rasool M, Yasmeen N, et al. Antibiotic resistance: one health one world outlook. Frontiers in Cellular and Infection Microbiology, 2021;11:771510.

- WHO. New report calls for urgent action to avert antimicrobial resistance crisis. World Health Organization. 2019.

- Hamed S.L. Detection of insertion sequence isaba1 among clinical isolates of Carbapenems-resistant Acinetobacter baumannii. Al Mustansiriyah Journal of Pharmaceutical Sciences. 2014;14(1):128-35.

- Lee CR, Lee JH, Park M, Park KS, Bae IK, Kim YB, et al. Biology of acinetobacter baumannii: pathogenesis, antibiotic resistance mechanisms, and prospective treatment options. Frontiers in Cellular and Infection Microbiology, 2017;7, 55.

- Singh R, Vora J, Nadhe SB, Wadhwani Sa, Shedbalkar UU, Chopade Ba. Antibacterial activities of bacteriagenic silver nanoparticles against nosocomial Acinetobacter baumannii. Journal of Nanoscience and Nanotechnology. 2018;18(6):3806-15.

- Havenga B, Reyneke B, Waso-Reyneke M, Ndlovu T, Khan S, Khan W. Biological control of Acinetobacter baumannii: in vitro and in vivo activity, limitations, and combination therapies. Microorganisms. 2022;10(5).

- Sarshar M, Behzadi P, Scribano D, Palamara At, Ambrosi C. Acinetobacter baumannii: an ancient commensal with weapons of a pathogen. Pathogens. 2021;10(4).

- CDC. Antibiotic resistance threats in the united states. CDC, 2019.

- Ayoub Moubareck C, Hammoudi Halat D. Insights into Acinetobacter baumannii: a review of microbiological, virulence, and resistance traits in a threatening nosocomial pathogen. Antibiotics (basel). 2020;9(3).

- Upmanyu K, Haq QR, Singh R. Factors mediating Acinetobacter baumannii biofilm formation: opportunities for developing therapeutics. Current Research in Microbial Sciences. 2022;3:100131.

- Singh R, Nadhe S, Wadhwani S, Shedbalkar U, Chopade BA. Nanoparticles for control of biofilms of Acinetobacter species. Materials (Basel). 2016;9(5).

- Roy S, Chowdhury G, Mukhopadhyay AK, Dutta S, Basu S. Convergence of biofilm formation and antibiotic resistance in acinetobacter baumannii infection. Frontiers in Medicine, 2022;9:793615.

- Morris FC, Dexter C, Kostoulias X, Uddin MI, Peleg AY. The mechanisms of disease caused by acinetobacter baumannii. Frontiers in Microbiologyl. 2019;10:1601.

- Salih T, Salih HA. In silico design and molecular docking studies of carbapenem analogues targeting acinetobacter baumannii pbp1a receptor. Al Mustansiriyah Journal of Pharmaceutical Sciences. 2020;20(3):35-50.

- Jalali Y, Jalali M, Payer J. Acinetobacter baumannii: emergence of a superbug, past, present, and future. In: Guillermo T-I, editor. The Global Antimicrobial Resistance Epidemic. Rijeka: IntechOpen; 2022. Ch. 13.

- Lahiri D, Nag M, Sheikh HI, Sarkar T, Edinur HA, Pati S, et al. Microbiologically-synthesized nanoparticles and their role in silencing the biofilm signaling cascade. Frontiers in Microbiology. 2021;12.

- Mateo EM, Jiménez M. Silver nanoparticle-based therapy: can it be useful to combat multi-drug resistant bacteria? Antibiotics (basel). 2022;11(9).

- Almatroudi a. Silver nanoparticles: synthesis, characterisation and biomedical applications. Open Life Science. 2020;15(1):819-39.

- Busi Ss, Rajkumari J. Chapter 15 - microbially synthesized nanoparticles as next generation antimicrobials: scope and applications. In: grumezescu am, editor. Nanoparticles in pharmacotherapy: william andrew publishing; 2019. P. 485-524.

- Mukherjee S, Nethi SK. Biological synthesis of nanoparticles using bacteria. In: Panpatte DG, Jhala YK, editors. Nanotechnology for agriculture: advances for sustainable agriculture. Singapore: Springer Singapore; 2019. P. 37-51.

- Gondil VS, Kalaiyarasan T, Bharti VK, Chhibber S. Antibiofilm potential of seabuckthorn silver nanoparticles against Pseudomonas aeruginosa. 3 Biotech. 2019;9(11):402.

- Swidan NS, Hashem YA, Elkhatib WF, Yassien MA. Antibiofilm activity of green synthesized silver nanoparticles against biofilm associated enterococcal urinary pathogens. Scientific Reports. 2022;12(1):3869.

- Dias DE Emery B, Zottis Chitolina G, Qadir MI, Quedi Furian T, Apellanis Borges K, De Souza Moraes Hl, et al. Antimicrobial and antibiofilm activity of silver nanoparticles against salmonella enteritidis. Brazillian Journal of Microbiology. 2022.

- Ahamad I, Bano F, Anwer R, Srivastava P, Kumar R, Fatma T. Antibiofilm activities of biogenic silver nanoparticles against Candida albicans. Frontiers in Microbiology. 2021;12:741493.

- Tille PM. Bailey & Scott'sDiagnostic Microbiology, 15th edition. 2021:1184.

- Wayne p. Performance standards for antimicrobial susceptibility testing, 30th ed. CLSI, 2020.

- Limban C, Marutescu L, Chifiriuc MC. Synthesis, spectroscopic properties and antipathogenic activity of new thiourea derivatives. Molecules. 2011;16(9):7593-607.

- Nirmala C, Sridevi M. Characterization, antimicrobial and antioxidant evaluation of biofabricated silver nanoparticles from endophytic pantoea anthophila. Journal of Inorganic and Organometallic Polymers and Materials. 2021;31(9):3711-25.

- Singh R, Shedbalkar UU, Wadhwani SA, Chopade BA. Bacteriagenic silver nanoparticles: synthesis, mechanism, and applications. Applied Microbiology and Biotechnology. 2015;99(11):4579-93.

- Hetta HF, Al-kadmy IM, Kkhazaal SS, Abbas S, Suhail A, El-Mokhtar MA, et al. Antibiofilm and antivirulence potential of silver nanoparticles against multidrug-resistant Acinetobacter baumannii. Scientific Reports. 2021;11(1):10751.

- CLSI. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard. 10th ed. 2018.

- Ahmed AA, Salih FA. Quercus infectoria gall extracts reduce quorum sensing-controlled virulence factors production and biofilm formation in Pseudomonas aeruginosa recovered from burn wounds. BMC Complementary and Alternative Medicine. 2019;19(1):177.

- Thirapanmethee K, Srisiri-A-Nun T, Houngsaitong J, Montakantikul P, Khuntayaporn P, Chomnawang M. Prevalence of oxa-type β-lactamase genes among carbapenem-resistant Acinetobacter baumannii clinical isolates in thailand. Antibiotics. 2020;9:864.

- Muhsin SS, Bakir WA, Sabbah MA. Identification and sequencing of ISAba2 of Acinetobacter baumannii isolated from baghdad hospitals. Mustansiriya Medical Journal, 2022, 1;21(1):30.

- Li YJ, Pan CZ, Fang CQ, Zhao ZX, Chen HL, Guo PH, et al. Pneumonia caused by extensive drug-resistant Acinetobacter baumannii among hospitalized patients: genetic relationships, risk factors and mortality. Bmc Infectious Diseases. 2017;17(1):371.

- Buchhorn DE Freitas S, hartwig DD. Promising targets for immunotherapeutic approaches against Acinetobacter baumannii. Microbial Pathogenesis. 2022;173:105855.

- Vázquez-lópez R Solano-Gálvez SG, Juárez Vignon-Whaley JJ, Abello Vaamonde JA, Padró Alonzo LA, Rivera Reséndiz A, et al. Acinetobacter baumannii resistance: a real challenge for clinicians. Antibiotics (Basel). 2020;9(4).

- Maspi H, Mahmoodzadeh Hosseini H, Amin M, Imani Fooladi AA. High prevalence of extensively drug-resistant and metallo beta-lactamase-producing clinical Acinetobacter baumannii in iran. Microbial Pathogenesis. 2016;98:155-9.

- Hall CW, Mah TF. Molecular mechanisms of biofilm-based antibiotic resistance and tolerance in pathogenic bacteria. FEMS in Microbiology Reviews. 2017;41(3):276-301.

- Haji SH, Ali FA, Aka ST. Synergistic antibacterial activity of silver nanoparticles biosynthesized by carbapenem-resistant Gram-negative bacilli. Scientific Reports, 2022, 9;12(1):15254.

- He R, Qian X, Yin J, Zhu Z-Kjjomc. Preparation of polychrome silver nanoparticles in different solvents. Journal of Materials Chemistry. 2002;12(12):3783-6.

- Bhatt D, Gupta E, Kaushik S, Srivastava VK, Saxena J, Jyoti A. Bio-fabrication of silver nanoparticles by Pseudomonas aeruginosa: optimisation and antibacterial activity against selected waterborne human pathogens. IET nanobiotechnology. 2018;12(7):981-6.

- Peiris MK, Gunasekara CP, Jayaweera PM, Arachchi ND, Fernando N. Biosynthesized silver nanoparticles: are they effective antimicrobials? Memórias do Instituto Oswaldo Cruz.. 2017;112(8):537-43.

- Jain as, pawar ps, sarkar a, junnuthula v, dyawanapelly s. Bionanofactories for green synthesis of silver nanoparticles: toward antimicrobial applications. Intenational Journal of Molecular Sciences. 2021;22(21).

- Ahmed FY, Farghaly Aly U, Abd El-Baky RM, Waly NG. Comparative study of antibacterial effects of titanium dioxide nanoparticles alone and in combination with antibiotics on mdr pseudomonas aeruginosa strains. International Journal of Nanomedicine. 2020.

- Sobha K, Dmp P, Anantha R, Verma M, Surendranath K. Evaluation of therapeutic potential of the silver/silver chloride nanoparticles synthesized with the aqueous leaf extract of rumex acetosa open. Scientific Reports. 2017;7.

- Abootalebi s, mousavi sm, hashemi sa, shorafa e, omidifar n, gholami a. Antibacterial effect of green synthesized silver nanoparticles using ferula assafoetida against acinetobacter baumannii isolated from the hospital and their cytotoxicity on the human cell line. Journal of Nanomaterials. 2021;2021.

- Ibrahim E, Fouad H, Zhang M, Zhang Y, Qiu W, Yan C, et al. Biosynthesis of silver nanoparticles using endophytic bacteria and their role in inhibition of rice pathogenic bacteria and plant growth promotion. RSC Advances. 2019;9(50):29293-9.

- Kumar CG, Mamidyala SK. Extracellular synthesis of silver nanoparticles using culture supernatant of pseudomonas aeruginosa. Colloids and Surfaces B: Biointerfaces. 2011;84(2):462-6.

- Zhong S, He S. Quorum sensing inhibition or quenching in Acinetobacter baumannii: the novel therapeutic strategies for new drug development. Frontiers in Microbiology, 2021;12:558003.

- Santajit S, Sookrung N, Indrawattana N. Quorum sensing in eskape bugs: a target for combating antimicrobial resistance and bacterial virulence. Biology (Basel). 2022;11(10).

- Sionov RV, Steinberg D. Targeting the holy triangle of quorum sensing, biofilm formation, and antibiotic resistance in pathogenic bacteria. Microorganisms, 2022; 10(6).